A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.
Dewpoint Therapeutics Inc. has nominated a second development candidate, DPTX-3496. The oral, small-molecule condensate modulator targets β-catenin to address Wnt-driven colorectal cancer, triple-negative breast cancer and non-small-cell lung cancer. IND-enabling studies have commenced, with an IND filing planned in the second half of this year.
Some favorable and some not-so-great results from separate midstage trials testing the anti-dickkopf homolog 1 antibody sirexatamab in combo regimens for two types of gastrointestinal tumors vexed Leap Therapeutics Inc. (NASDAQ:LPTX), shares of which ended Jan. 28 at 66 cents, down $1.60, or 71%.
At the recent ASCO Gastrointestinal Cancers symposium, Cyclacel Ltd. presented preclinical data for the Polo-like kinase 1 (PLK1) inhibitor plogosertib from assessment in models of colorectal cancer.
A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about initial phase II data from Xilio Therapeutics Inc.’s ongoing trial with vilastobart (XTX-101) when paired with PD-L1-blocking antibody Tecentriq (atezolizumab, Roche AG) in metastatic microsatellite stable disease.
A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.
Arrivent Biopharma Inc. has entered into an exclusive license agreement with Lepu Biopharma Co. Ltd. for MRG-007, an antibody-drug conjugate (ADC) in development for gastrointestinal cancers.
Colorectal cancer remains the third most common malignancy worldwide, with advanced stages presenting significant challenges for treatment. A recently published study highlights the potential of combining the antiangiogenic peptide TB-01 (PEP-06), a drug in phase II studies in China, with the approved cytotoxic drug trifluridine/tipiracil (TAS-102) as a treatment for colorectal cancer.
Researchers from the National Health Research Institutes of Taiwan described the efficacy of BPR1J481, a multitarget tyrosine kinase inhibitor in PDX-derived colorectal cancer cells, which retain the original PDX tumor characteristics.
